OBJECTIVES: Significant coronary artery disease (CAD) is common among patients currently evaluated for transcatheter aortic valve implantation (TAVI). Limited data exist on the outcome of patients undergoing combined transcatheter treatment of aortic valve disease and CAD. The aim of the study was to analyse the impact of concomitant percutaneous coronary intervention (PCI) on early and late clinical outcomes of patients receiving TAVI.
INTRODUCTION
The majority of patients currently evaluated for transcatheter aortic valve implantation (TAVI) are older than 75 years [1] [2] [3] . Not surprisingly, cardiac catheterization often reveals coexisting coronary artery disease (CAD). There is discrepant data on the impact of CAD on prognosis of TAVI-treated patients [4] [5] [6] [7] [8] [9] . Additionally, it is yet unsolved how to manage significant CAD in this population and how to define the indication for coronary intervention in the particular context of TAVI.
For patients eligible for conventional aortic valve surgery, current guidelines recommend complete myocardial revascularization for coronary artery diameter stenosis ≥70% (Class IC) and 50-70% (Class IIaC) [10, 11] . This is routinely achieved by synchronous coronary artery bypass grafting (CABG). In patients receiving surgical aortic valve replacement (SAVR), untreated CAD is associated with higher rates of perioperative myocardial infarction, increased perioperative mortality and poorer long-term outcome.
On the other hand, mortality rates of combined SAVR and CABG are-especially in elderly patients-significantly higher compared with isolated SAVR [12] [13] [14] [15] [16] [17] .
The PARTNER trial excluded patients with untreated clinically significant CAD requiring revascularization and any therapeutic invasive cardiac procedure performed within 30 days (for stable angina or treatment of acute coronary syndrome) of the index procedure (or 6 months if the procedure was a drug-eluting coronary stent implantation) [1, 2] . A few smaller studies have analysed the outcome of patients treated with a combination of TAVI and percutaneous coronary intervention (PCI) and reported high rates of procedural success and efficacy with comparable periprocedural mortality when compared with those receiving isolated TAVI [18] [19] [20] .
The aim of our study was to analyse the impact of coronary intervention-based on current heart team practice-on early and late outcomes after transcatheter treatment of aortic valve disease.
METHODS

Study population
Between January 2009 and December 2012, 411 TAVIs were performed at our institution. Patients suffered from severe aortic valve stenosis (n = 388; dp mean > 40 mmHg, AVA <1.0 cm 2 ) or severely degenerated bioprostheses (n = 23). Patients were evaluated for TAVI when they were (i) inoperable or at high risk (logistic EuroSCORE >20%), (ii) were ≥80 years, (iii) were <80 years but had relevant comorbidities, e.g. prior cardiac surgery or (iv) had significant other comorbidities, e.g. porcelain aorta, liver cirrhosis or severe obesity. Preoperative diagnostic procedures included echocardiography, cardiac catheterization and multislice computed tomography for aortic root measurements and quantitative angiography of the aorta and iliofemoral vessels. All patients gave written informed consent. Follow-up was performed by periodical phone calls to analyse all-cause mortality.
Heart team
All candidates were discussed within our interdisciplinary (interventional cardiology and cardiac surgery) heart team. The heart team decided on indication for valve therapy, a form of valve therapy-in the case of TAVI-access route and transcatheter heart valve (THV) system to be used. With regard to co-existing CAD, indication for coronary revascularization was based on current practice.
Procedural settings and transcatheter heart valve systems PCI was performed by standard techniques either as staged procedure upfront of the valve therapy or at the beginning of the TAVI. Planned PCI was performed ahead of the TAVI procedure to avoid guiding catheter interference by the THV and to reduce potential risks of ischaemia-mediated complications during rapid pacing. There was no specific algorithm on staged versus synchronous PCI. The decision was left to the interventionalist and/or patient preference. Patients requiring unplanned PCI or CABG for coronary obstruction after THV implantation were allocated to the isolated-TAVI group. All TAVI procedures were performed in a hybrid operating room under general anaesthesia as previously described [21] . The access route was either transfemoral or transapical. THV systems were the Edwards SAPIEN and SAPIEN XT systems (Edwards Lifesciences, Irvine, CA, USA), the Medtronic CoreValve (Medtronic, Minneapolis, MN, USA) and the Acurate TA prosthesis (Symetis, Ecublens, Switzerland). THV devices were handled according to the manufacturers' instructions. All TAVI operators were certified users. Since May 2010, percutaneous closure of the femoral access site was achieved by the double-ProGlide preclose technique as previously described [22] . All patients were under aspirin and received a therapeutic dose of unfractionated heparin during the procedure. All patients were transferred to the ICU after the procedure.
Endpoints
Standardized endpoints were used according to the current definitions of the valve academic research consortium (VARC)-2 [23] and were reported following the TAVI index procedure. Emergency cardiac surgery was defined as previously described [21] , briefly being any intervention of the cardiac surgeon for procedural complications within the first 24 h regardless of the use of cardiopulmonary bypass or access route (e.g. with or without sternotomy).
Meta-analysis
Literature search (NCBI PubMed) identified five studies reporting the combination of TAVI with CAD treatment [4, 5, [18] [19] [20] . Only two provided data on both TAVI and TAVI + PCI results [18, 20] . Reported 30-day mortality rates were pooled with our cohort and tested by meta-regression analysis for statistical significance.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) and were compared using a two-sided Student's t-test. Chisquared or two-tailed Fisher's exact test was performed as appropriate to compare categorical variables ( presented as number and percentage). Kaplan-Meier method was used to obtain and analyse survival curves based on all available follow-up data. Groups were compared by the log-rank test. Univariate Cox proportional hazards regression was performed to analyse the effect of PCI on mortality and presented as odds ratio (OR) with the respective 95% confidence interval (CI). Follow-up time was calculated by the reverse Kaplan-Meier method. A P-value <0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed with the use of XLSTAT Version 2013.5.02 (Addinsoft). Meta-regression analysis was performed with the use of Comprehensive Meta-Analysis Version 2.2 (Biostat, Englewood, NJ, USA).
RESULTS
Baseline characteristics
Overall, 411 TAVIs were performed. In 65 patients (16%), valve therapy was combined with planned PCI (Table 1) . One hundred and ninety patients were treated by a transfemoral route, and of these, 33 (17%) were treated in combination with PCI. Two hundred and twenty-one patients were treated by a transapical route, and of these, 32 (15%) had concomitant PCI. Three hundred and forty-six patients received isolated TAVI. Mean age was 82 years (P = 0.92) in both groups. About 86% (TAVI + PCI) and 81% (TAVI; P = 0.26) were in NYHA functional class III or IV. Logistic EuroSCORE was 21.7 ± 13.9% (TAVI + PCI) and 20.3 ± 14.6% (TAVI; P = 0.47). There were no significant differences between the two groups with respect to diabetes, left ventricular performance, previous cardiac surgery or PCI, atrial fibrillation or renal function.
Myocardial revascularization
PCI was performed as part of a single procedure in 26% of the cases and as a staged procedure in 74% with a mean interval of 36 days ahead of the valve intervention (Table 2) . PCI was successfully accomplished in all cases. In 95%, only one coronary was treated. PCI was mostly performed in native arteries. Bare metal stents were implanted in 71%. The average number of stents was 1.3 per patient.
Transcatheter valve therapy
TAVI procedures were performed under general anaesthesia in a hybrid operating theatre (Table 3) . Twenty-three patients were treated as valve in valve for severely degenerated bioprosthesis. The Edwards SAPIEN device was used in more than 90% of the patients.
Clinical outcome and VARC-2 endpoints until Day 30
Death from any cause was significantly more frequent among patients receiving combination therapy TAVI + PCI (15 vs 5%; P = 0.01) ( Table 4) . Perioperative mortality was comparable between patients undergoing synchronous (18%) and staged PCI (15%; P = 1.00). There was a higher rate of myocardial infarction in the TAVI + PCI versus the isolated TAVI group (6 vs 1%; P = 0.01), especially with respect to the VARC-2-defined periprocedural myocardial infarctions (MIs; 5 vs 1%; P = 0.05). The rate of neurological complications (stroke and transitoric ischaemic attack) was low and not significantly different between the two groups (TAVI + PCI 0% vs TAVI 2%; P = 0.60). About 44% of the patients in both groups required blood transfusion following the index procedure. There was a trend towards an increased requirement for transfusion in the staged PCI group (50 vs 29%), but this did not reach statistical significance (P = 0.14). The incidence of VARC-2 minor, major and life-threatening bleeding complications was similar among groups. Severe kidney injury requiring renal replacement therapy was not different among the groups. The incidence of vascular access-related complications was not different among groups. ProGlide suture-mediated transcutaneous closure of the femoral access site was equally effective and safe in both groups. The requirement for unplanned cardiosurgical intervention was not elevated in TAVI + PCI. Cases of the early deceased patients of the TAVI-PCI group are described in Table 5 .
Two-year Kaplan-Meier survival estimates
Follow-up was available for n = 411 patients (100%). Median follow-up was 16 months with an interquartile range of 4-26 Values are n (%). OR: operating room; THV: transcatheter heart valve.
months. Late outcome was significantly poorer in TAVI + PCI, compared with isolated TAVI (P = 0.03) (Fig. 1) . Mean survival time was reduced from 32 ± 1 months (TAVI) to 26 ± 3 months (TAVI + PCI). Estimated survival rates were 1-year TAVI 78 ± 2% (95% CI 74-83) vs 1-year TAVI + PCI 67 ± 7% (95% CI 53-80) and 2-year TAVI 72 ± 3% (95% CI 66-78) vs 2-year TAVI + PCI 52 ± 8% (95% CI 36-69), respectively. Univariate Cox regression calculated an OR of 1.66 (95% CI 1.03-2.66; P = 0.04) for death from any cause associated with concomitant PCI. Kaplan-Meier 2-year survival was not different between patients receiving staged or synchronous PCI (P = 0.65) (data not shown).
Meta-analysis of current TAVI + PCI studies
Literature search identified two other studies that focused on the comparison of TAVI + PCI versus TAVI alone [19, 21] . When combining these two studies with our analysis, the pooled cohort contained 792 patients. Meta-regression analysis calculated an OR of 2.26 (95% CI 1.22-4.21; P = 0.01) ( Table 6 ).
DISCUSSION
With the development of TAVI, many elderly and high-risk patients can now be offered a minimal-invasive and effective therapy of aortic valve disease. CAD is frequently encountered in this patient population. There are conflicting data about CAD as a predictor for increased mortality in this context [1] [2] [3] [4] [5] [6] [7] [8] .
Concomitant myocardial revascularization is associated with an elevated risk for myocardial infarction and death
The key finding of our study is that TAVI patients receiving combined treatment of both aortic valve disease and CAD have markedly adverse outcome compared with those undergoing isolated TAVI. Associated with an increased rate of myocardial infarctions, perioperative mortality was 3-fold increased-regardless of synchronous or staged strategy for PCI. Adverse impact of Values are n (%) or mean ± SD. VARC: valve academic research consortium; RBC: packed red blood cells; AKI: acute kidney injury; CPB: cardiopulmonary bypass; THV: transcatheter heart valve; TIA: transitoric ischaemic attack; THV: transcatheter heart valve.
concomitant PCI was seen throughout the follow-up. KaplanMeier 2-year cumulative survival was significantly deteriorated.
We calculated an OR of 1.66 for death in the case of concomitant PCI. We could confirm our finding by means of a pooled analysis of our study together with the results of two smaller TAVI + PCI studies [19, 21] , and found by meta-regression analysis that for the pooled cohort perioperative mortality was significantly more than 2-fold elevated. It has to be noted, however, that the three study populations were inhomogenous and that in the study by Wenaweser et al. [20] , more patients (73% vs 29% in our study) received implantation of a drug-eluting stent (DES). This might account for some of the differences, especially with regard to the mid-and long-term outcomes.
We estimated a 1-year survival rate of 67% in the TAVI + PCI group. This is not too different from the 50% 1-year survival rate estimated in the 179 inoperable PARTNER patients receiving only standard therapy [1] . The prognostic benefit of TAVI + PCI for elderly patients requiring combined treatment of aortic valve stenosis and significant CAD might therefore be small-or not even present at all. It is also unclear yet how conventional surgery would perform in a direct comparison in this group of patients.
Results of transcatheter treatment analogous to conventional surgery
Our result that concomitant PCI was associated with poorer outcome in TAVI patients is in accordance with the majority of reported evidence in the surgical literature [12] [13] [14] [15] [16] [17] . The 2008 analysis of the society of thoracic surgeons database revealed perioperative death rates for all patients of 3% for SAVR and 7% for SAVR + CABG, respectively [13, 14] . Patients of advanced age (>80 years) and with previous cardiac surgery (which accounted for 25% of our TAVI population) were at significantly higher risk of dying perioperatively (ORs 2.11-3.34) [13, 14] . A multicentre cohort study of 7584 patients undergoing SAVR between November 1987 and June 2006 by Likosky et al. [15] reported for the SAVR group a 30-day mortality of 4% for patients <80 years, 7% for patients 80-84 years and 12% for patients ≥85 years. Among patients undergoing synchronous SAVR + CABG, 30-day mortality was 6% (<80), 9.4% (80-84) and 9% (≥85). There is only a single study by Melby et al. [16] that reported improved early and late mortality in 245 patients ≥80 years receiving synchronous CABG compared with lone SAVR. The number of bypass grafts did not affect survival after SAVR + CABG [17] .
PCI in TAVI patients with high procedural success rate
We identified in 16% of the patients coronary lesions that-after discussion within the heart team-were decided to receive concomitant treatment. As noted by others, revascularization could be achieved by PCI with high rates of procedural success indicating therapeutic efficacy [18] [19] [20] . When interpreting our result, it should be kept in mind that due to our TAVI evaluation and selection process, all patients had coronary lesions that were favourable for PCI. In most cases, only a single vessel was treated. Some patients were initially evaluated for TAVI but subsequently switched to surgical or conservative therapy because of advanced CAD. These patients were not distinctly followed and cannot be compared with the patients undergoing transcatheter treatment.
Higher incidence of myocardial infarction with concomitant percutaneous coronary intervention
One mechanism responsible for the increased mortality rate in the PCI group was an accumulation of myocardial infarction (especially periprocedural), whereas all other VARC-2 endpoints, including stroke, vascular access-related and bleeding complications occurred with comparable frequencies. It is impossible to differentiate whether the underlying disease or the active revascularization procedure (or both) was responsible for the adverse outcome. We predominantly implanted Edwards SAPIEN prostheses, but we do not believe that the type of THV device used had an impact on the outcome of concomitantly revascularized patients.
Current guidelines on myocardial revascularisation for patients undergoing valve therapy
For patients undergoing conventional SAVR, there are clear guidelines on how to manage significant CAD during the operation [10, 11] . There is a Class I recommendation for revascularization of coronary artery diameter stenosis ≥70% and a Class IIa recommendation for stenosis between 50 and 70%. It is noteworthy that both recommendations have a level of evidence C and are not based on randomized clinical trials. Our data raise the general question of what impact significant CAD has on symptoms and prognosis of elderly patients successfully treated by TAVI. There are several directions to interpret our result: (i) underlying CAD should be treated conservatively, (ii) underlying CAD should be treated more aggressively, eventually even in these high-risk patients by conventional surgery. We and others believe that fractional flow reserve evaluation might add important information in this context [24] , (iii) PCI or CABG add too many complications to the valve therapy and that despite effective revascularization there is no net-benefit, or (iv) the natural course of the advanced cardiac disease (valvular disease plus CAD) cannot be delayed in these elderly patients by any form of current therapy.
Randomized studies are required to test the current practice on myocardial revascularization for patients receiving transcatheter therapy of aortic valve disease.
Limitations of the study
The observational design of the registry and the single-centre experience is associated with inherent limitations. The institutional heart team decided in a non-randomized fashion as to the form of valve therapy and the requirement for PCI. As a consequence, selected patients had favourable anatomy for both TAVI and PCI. There was also no defined algorithm regarding the time point of PCI. We defined the TAVI as an index procedure and analysed 
CONCLUSIONS
Selected patients can be treated percutaneously for both CAD and aortic valve disease with high rates of procedural success. However, combined treatment is associated with an increased rate of myocardial infarction and higher periprocedural mortality. Adverse effect on mortality was evident throughout the 2-year follow-up. Future randomized clinical trials will have to define standards on myocardial revascularization for elderly patients undergoing TAVI.
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